Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Retained Earnings: 2023-2024

Historic Retained Earnings for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to -$400.0 million.

  • BioLineRx's Retained Earnings fell 2.00% to -$398.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$398.6 million, marking a year-over-year decrease of 2.00%. This contributed to the annual value of -$400.0 million for FY2024, which is 2.40% down from last year.
  • According to the latest figures from FY2024, BioLineRx's Retained Earnings is -$400.0 million, which was down 2.40% from -$390.6 million recorded in FY2023.
  • BioLineRx's 5-year Retained Earnings high stood at -$390.6 million for FY2023, and its period low was -$400.0 million during FY2024.
  • Over the past 2 years, BioLineRx's median Retained Earnings value was -$395.3 million (recorded in 2023), while the average stood at -$395.3 million.
  • Data for BioLineRx's Retained Earnings shows a maximum YoY declined of 2.40% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Retained Earnings (Yearly) stood at -$390.6 million in 2023, then dropped by 2.40% to -$400.0 million in 2024.